Making Medicine

What if the next breakthrough medicine comes from China? Should American patients care where it was discovered? John Stanford and Max Bayer of @endpts examine the ethical questions surrounding proposed COINS Act restrictions. Check out the full episode on YouTube @MakingMedicinePod #COINSAct #ChinaBiotech #PatientAccess

Treasury's proposed COINS Act rules acknowledge potential risks to U.S. public health and American companies. What could that mean for biotech investment and patients? John Stanford and Max Bayer examine the implications on Making Medicine. Check out the full episode on YouTube @MakingMedicinePod #COINSAct #BiotechPolicy

Treasury says licensing isn't included in its proposed COINS Act rules. But what about biotech co-development and joint ventures? Max Bayer of @endpts joins John Stanford on Making Medicine to explain the uncertainty. Check out the full episode on YouTube @MakingMedicinePod #COINSAct #ChinaBiotech

Slowing China's biotech growth won't automatically strengthen America's. John Stanford argues that U.S. leadership depends on stronger research, venture investment, entrepreneurship, and FDA modernization. How should America compete? #AmericanBiotech #ChinaBiotech

Should it matter where a new medicine was first discovered? John Stanford examines how global biotech partnerships can support American drug development, and why restricting them may have consequences for patients. #Biotech #Innovation #Biotechnology @johnbstanford @MedicineMa80739 @incub8coalition @SMMT_TX